Sugi Predict

Sugi Predict / Compounds / SCHEMBL288702

SCHEMBL288702

SCHEMBL288702

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4[C@@H](O)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 4/20 0.69
▸ RORC P51449 3/20 0.69
▸ USP2 O75604 2/20 0.69
▸ CYP46A1 Q9Y6A2 2/20 0.69
▸ OSBP2 Q969R2 2/20 0.69
▸ LMNA P02545 1/20 0.69
▸ ABCB1 P08183 1/20 0.69
▸ SRD5A1 P18405 3/20 0.61
▸ GRIN1 Q05586 2/20 0.58
▸ GRIN2A Q12879 2/20 0.58
▸ NR1H3 Q13133 2/20 0.58
▸ NPC1L1 Q9UHC9 2/20 0.57
▸ POLA1 P09884 1/20 0.57
▸ FNTA P49354 1/20 0.56
▸ FNTB P49356 1/20 0.56
▸ CRYAB P02511 1/20 0.55
▸ HMGCR P04035 1/20 0.55
▸ ITGB3 P05106 1/20 0.55
▸ ITGAV P06756 1/20 0.55
▸ SREBF2 Q12772 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336003 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL28750282 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL289374 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL1917363 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL6390184 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL6387159 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL3350440 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL336002 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL22032772 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL26642855 1.00 OSBP (0.69) OSBPRORCUSP2CYP46A1OSBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2592420-B1 Method and use of metabolic compounds for diagnosing stroke INFANDX AG (DE) 2017-09-20 — — EP claimed
US-20120136581-A1 Method of Diagnosing Asphyxia BIOCRATES LIFE SCIENCES AG (AT) 2012-05-31 — — US claimed
EP-2427773-A1 METHOD OF DIAGNOSING ASPHYXIA Keller, Matthias (DE) 2012-03-14 — — EP claimed
WO-2011006087-A1 INHIBITION OF PPAR GAMMA EXPRESSION IN PREADIPOCYTE CELLS BY OXYSTEROLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-01-13 — — WO claimed
WO-2010128054-A1 METHOD OF DIAGNOSING ASPHYXIA BIOCRATES LIFE SCIENCES AG (AT) 2010-11-11 — — WO claimed
EP-2249161-A1 Method of diagnosing asphyxia BIOCRATES Life Sciences AG (AT) 2010-11-10 — — EP claimed
US-20100112030-A1 ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-05-06 — — US claimed
EP-2111225-A2 INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS The Regents Of The University Of California (US) 2009-10-28 — — EP claimed
US-20090202660-A1 Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-08-13 — — US claimed
WO-2008082520-A2 INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-07-10 — — WO claimed
US-20030032824-A1 Meiosis regulating compounds GRONDAHL CHRISTIAN (DK) 2003-02-13 — — US claimed
US-20020183283-A1 Meiosis regulating compounds FAARUP PETER (DK) 2002-12-05 — — US claimed
US-20010005757-A1 Meiosis regulating compounds GRONDAHL CHRISTIAN (DK) 2001-06-28 — — US claimed
US-20010003782-A1 Meiosis regulating compounds NOVA NORDISK A/S (DK) 2001-06-14 — — US claimed
EP-1077992-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 2001-02-28 — — EP claimed
US-6184215-B1 TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-02-06 — — US claimed
WO-2000049992-A2 USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-08-31 — — WO claimed
WO-1999058549-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1999-11-18 — — WO claimed
EP-0946584-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1999-10-06 — — EP claimed
WO-1998028323-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1998-07-02 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183283-A1 Meiosis regulating compounds SREBF2, SREBF1, TRIP13 OSBP 6/4885RORC 872/4885USP2 1879/4885
US-20100112030-A1 ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE SHH, SMO, GLI1 OSBP 14/4885RORC 134/4885USP2 1120/4885
US-20030032824-A1 Meiosis regulating compounds MNS1, NR5A1, NASP OSBP 95/4885RORC 1053/4885USP2 4505/4885
US-20010003782-A1 Meiosis regulating compounds SREBF2, SREBF1, TRIP13 OSBP 6/4885RORC 872/4885USP2 1879/4885
US-20010005757-A1 Meiosis regulating compounds MNS1, NR5A1, NASP OSBP 95/4885RORC 1053/4885USP2 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback